Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results

Aims: The CV-CARE registry provides RWE in Canadian routine clinical practice. Methods: CV-CARE is a multi-site, observational, prospective Canadian registry enrolling patients initiating treatment with metformin hydrochloride extended-release (MetER) for T2D; colesevelam (C) for HCh; and azilsartan (AZI), azilsartan/chlorthalidone (AZI/CHL) or diltiazem extended-release (TXC) for HTN. Patient characteristics/assessment were performed at baseline and 12 +/- 6 months. Primary outcome was absolute change in HbA(1c) and FPG (MetER); % change in LDL-C (C); and absolute change in BP (AZI-AZI/CHL-TXC). Results: Of the 4194 patients in the primary analysis population, 24% were taking MetER, 39% were taking C, 33% were taking AZI, 12% were taking AZI/CHL, and 3% were taking TXC. At 12 months, MetER-treated patients had an absolute mean (95% CI) change in HbA(1c) of-0.3% [-0.4;-0.2] and in FPG of 0.7 mmol/L [-1.0;-0.4]. C-treated patients had a mean (95% CI) % change in LDL-C of-13.0% [-14.6;-11.4]. Absolute mean (95% CI) changes in SBP were-18.7 mmHg [-19.7; -17.7](AZI),-21.3 mmHg [-23.1; -19.5](AZI/CHL), and 12.3 mmHg [-15.1; -9.6](TXC). Conclusion: In a real-world Canadian setting, MetER, C, AZI, AZI/CHL, and TXC show improvement of the cardiometabolic profile of T2D, HCh, and HTN patients. (C) 2020 Elsevier B.V. All rights reserved.